Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Mar;108(3):776–779. doi: 10.1111/j.1476-5381.1993.tb12877.x

Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat.

J P Cristol 1, T D Warner 1, C Thiemermann 1, J R Vane 1
PMCID: PMC1908012  PMID: 8467364

Abstract

1. Using endothelin-1 (ET-1), endothelin-3 (ET-3), sarafotoxin 6b (SX6b) and sarafotoxin 6c (SX6c) as agonists and BQ-123 as a selective ETA receptor antagonist, we have examined the endothelin receptor subtypes mediating the systemic pressor and renal vasoconstrictor effects of the ET/SX family of peptides. 2. In anaesthetized rats, bolus intravenous injections of ET-1, ET-3, SX6b or SX6c (0.1, 0.25 and 0.50 nmol kg-1) produced initial transient depressor responses followed by sustained and dose-dependent increases in mean arterial pressure (MAP) with the following rank order of potency: SX6b > ET-1 >> SX6c > ET-3. In contrast, in the renal vasculature these peptides caused equipotent dose-dependent falls in renal blood flow (RBF) (ET-1 = ET-3 = SX6b = SX6c). 3. BQ-123 (1 mg kg-1, i.v. bolus) significantly reduced the systemic pressor effects of all the peptides but was largely ineffective against the renal vasoconstrictions. 4. These results indicate that although the systemic pressor effects of the ET/SX peptides are mediated via ETA receptors, the vasoconstriction in the kidney in vivo may be mediated predominantly via ETB-like receptors. This may be of therapeutic relevance, for an ETA-receptor-selective antagonist could offer only poor protection of the renal circulation from the deleterious effects of endogenously produced members of this peptide family.

Full text

PDF
776

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arai H., Hori S., Aramori I., Ohkubo H., Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature. 1990 Dec 20;348(6303):730–732. doi: 10.1038/348730a0. [DOI] [PubMed] [Google Scholar]
  2. Badr K. F., Murray J. J., Breyer M. D., Takahashi K., Inagami T., Harris R. C. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest. 1989 Jan;83(1):336–342. doi: 10.1172/JCI113880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brooks D. P., Contino L. C., Storer B., Ohlstein E. H. Increased endothelin excretion in rats with renal failure induced by partial nephrectomy. Br J Pharmacol. 1991 Dec;104(4):987–989. doi: 10.1111/j.1476-5381.1991.tb12537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Emori T., Hirata Y., Marumo F. Specific receptors for endothelin-3 in cultured bovine endothelial cells and its cellular mechanism of action. FEBS Lett. 1990 Apr 24;263(2):261–264. doi: 10.1016/0014-5793(90)81388-5. [DOI] [PubMed] [Google Scholar]
  5. Firth J. D., Ratcliffe P. J., Raine A. E., Ledingham J. G. Endothelin: an important factor in acute renal failure? Lancet. 1988 Nov 19;2(8621):1179–1182. doi: 10.1016/s0140-6736(88)90243-7. [DOI] [PubMed] [Google Scholar]
  6. Harrison V. J., Randriantsoa A., Schoeffter P. Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery. Br J Pharmacol. 1992 Mar;105(3):511–513. doi: 10.1111/j.1476-5381.1992.tb09009.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ihara M., Fukuroda T., Saeki T., Nishikibe M., Kojiri K., Suda H., Yano M. An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis. Biochem Biophys Res Commun. 1991 Jul 15;178(1):132–137. doi: 10.1016/0006-291x(91)91789-f. [DOI] [PubMed] [Google Scholar]
  8. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  9. Ihara M., Saeki T., Funabashi K., Nakamichi K., Yano M., Fukuroda T., Miyaji M., Nishikibe M., Ikemoto F. Two endothelin receptor subtypes in porcine arteries. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S119–S121. doi: 10.1097/00005344-199100177-00031. [DOI] [PubMed] [Google Scholar]
  10. King A. J., Brenner B. M., Anderson S. Endothelin: a potent renal and systemic vasoconstrictor peptide. Am J Physiol. 1989 Jun;256(6 Pt 2):F1051–F1058. doi: 10.1152/ajprenal.1989.256.6.F1051. [DOI] [PubMed] [Google Scholar]
  11. Kloog Y., Bousso-Mittler D., Bdolah A., Sokolovsky M. Three apparent receptor subtypes for the endothelin/sarafotoxin family. FEBS Lett. 1989 Aug 14;253(1-2):199–202. doi: 10.1016/0014-5793(89)80958-5. [DOI] [PubMed] [Google Scholar]
  12. Kon V., Sugiura M., Inagami T., Harvie B. R., Ichikawa I., Hoover R. L. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int. 1990 Jun;37(6):1487–1491. doi: 10.1038/ki.1990.139. [DOI] [PubMed] [Google Scholar]
  13. Kon V., Yoshioka T., Fogo A., Ichikawa I. Glomerular actions of endothelin in vivo. J Clin Invest. 1989 May;83(5):1762–1767. doi: 10.1172/JCI114079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Koyama H., Tabata T., Nishzawa Y., Inoue T., Morii H., Yamaji T. Plasma endothelin levels in patients with uraemia. Lancet. 1989 May 6;1(8645):991–992. doi: 10.1016/s0140-6736(89)92631-7. [DOI] [PubMed] [Google Scholar]
  15. Masaki T., Kimura S., Yanagisawa M., Goto K. Molecular and cellular mechanism of endothelin regulation. Implications for vascular function. Circulation. 1991 Oct;84(4):1457–1468. doi: 10.1161/01.cir.84.4.1457. [DOI] [PubMed] [Google Scholar]
  16. Miller W. L., Redfield M. M., Burnett J. C., Jr Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989 Jan;83(1):317–320. doi: 10.1172/JCI113876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature. 1990 Dec 20;348(6303):732–735. doi: 10.1038/348732a0. [DOI] [PubMed] [Google Scholar]
  18. Samson W. K., Skala K. D., Alexander B. D., Huang F. L. Pituitary site of action of endothelin: selective inhibition of prolactin release in vitro. Biochem Biophys Res Commun. 1990 Jun 15;169(2):737–743. doi: 10.1016/0006-291x(90)90393-2. [DOI] [PubMed] [Google Scholar]
  19. Warrens A. N., Cassidy M. J., Takahashi K., Ghatei M. A., Bloom S. R. Endothelin in renal failure. Nephrol Dial Transplant. 1990;5(6):418–422. doi: 10.1093/ndt/5.6.418. [DOI] [PubMed] [Google Scholar]
  20. Williams D. L., Jr, Jones K. L., Pettibone D. J., Lis E. V., Clineschmidt B. V. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem Biophys Res Commun. 1991 Mar 15;175(2):556–561. doi: 10.1016/0006-291x(91)91601-8. [DOI] [PubMed] [Google Scholar]
  21. de Nucci G., Thomas R., D'Orleans-Juste P., Antunes E., Walder C., Warner T. D., Vane J. R. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9797–9800. doi: 10.1073/pnas.85.24.9797. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES